What Is the Interaction between Urine C-Reactive Protein, Prostatic Inflammation, and Doxazosin Treatment in Patients with Benign Prostatic Hyperplasia? A Pilot Study

Introduction: It was aimed to show the relationship between benign prostatic hyperplasia and inflammation by measuring urinary C-reactive protein values before and after alpha-blocker treatment. Methods: A total of 71 patients with a total prostate-specific antigen <3.5 ng/mL, International Prostate Symptom Score >7, and maximum urinary flow rate <15 mL/s were included in the study. Doxazosin 4 mg p.o. once daily was started orally as an alpha-blocker treatment. Serum and urine C-reactive protein values, International Prostate Symptom Score, maximum urinary flow rate, and the post-void residual volume of patients were recorded at the first admission and in the first month of alpha-blocker treatment. Results: The mean age of the patients was 59.2 +/- 7.5 years. The mean serum C-reactive protein values of the patients at the first admission and follow-up were 2.62 +/- 1.8 (range, 0-5) mg/L and 2.83 +/- 1.6 (0-6) mg/L, respectively. The mean urine C-reactive protein values of the patients at the first admission and follow-up were 0.45 +/- 0.11 (range, 0.28-0.99) mg/L and 0.14 +/- 0.04 (range, 0.79-0.328) mg/L, respectively, which was statistically significantly different. In the subgroup analysis, the urine C-reactive protein level change was more prominent in severely symptomatic patients than in moderately symptomatic patients. Conclusion: Our results showed that C-reactive protein was detectable in urine, alpha-blocker treatment significantly reduced urine C-reactive protein levels, and the decrease was more prominent in severely symptomatic patients. (C) 2021 S. Karger AG, Basel

Automated summary

The study aimed to investigate the relationship between benign prostatic hyperplasia and inflammation by measuring urinary C-reactive protein levels before and after alpha-blocker treatment. The results showed that alpha-blocker treatment significantly reduced urine C-reactive protein levels, with a more prominent decrease in severely symptomatic patients.